A Phase 1/1b Study of MGCD516 in Patients With Advanced Solid Tumor Malignancies
Phase of Trial: Phase I
Latest Information Update: 09 Jul 2019
Price : $35 *
At a glance
- Drugs Sitravatinib (Primary)
- Indications Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Solid tumours
- Focus Adverse reactions; First in man; Pharmacokinetics; Proof of concept
- Sponsors MethylGene; Mirati Therapeutics
- 03 Jul 2019 Planned End Date changed from 1 Sep 2019 to 1 Mar 2020.
- 03 Jul 2019 Planned primary completion date changed from 1 Jun 2019 to 1 Dec 2019.
- 17 Dec 2018 Planned End Date changed from 1 Mar 2019 to 1 Sep 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History